SCHEMBL703012

SCHEMBL703012

NS(=O)(=O)c1ccc(-c2ccc(/C=C3\C(=O)Nc4ccc(Cl)cc43)o2)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.85
KMT2A Q03164 9/20 0.85
POLB P06746 6/20 0.85
GAA P10253 2/20 0.85
PKM P14618 2/20 0.85
MAPT P10636 2/20 0.85
PPARG P37231 1/20 0.85
NCOA2 Q15596 1/20 0.85
NCOA1 Q15788 1/20 0.85
G6PD P11413 1/20 0.65
GFER P55789 1/20 0.65
L3MBTL1 Q9Y468 4/20 0.63
KDM4E B2RXH2 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
KLKB1 P03952 1/20 0.55
CTSB P07858 1/20 0.55
ELANE P08246 1/20 0.55
CTRB1 P17538 1/20 0.55
ALDH1A1 P00352 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL703013 1.00 MEN1 (0.85) MEN1KMT2APOLBGAAPKM
SCHEMBL10091732 1.00 MEN1 (0.85) MEN1KMT2APOLBGAAPKM
SCHEMBL10091725 0.84 MEN1 (0.61) MEN1KMT2APOLBGAAPKM
SCHEMBL10091727 0.83 MEN1 (0.60) MEN1KMT2APOLBGAAPKM
SCHEMBL10091726 0.78 PIM1 (0.56) MEN1KMT2APOLBGAAPKM
SCHEMBL5145439 0.78 MEN1 (1.00) MEN1KMT2APOLBGAAPKM
SCHEMBL706219 0.77 PIM1 (0.71) MEN1KMT2APOLBGAAPKM
SCHEMBL10091754 0.77 PIM1 (0.71) MEN1KMT2APOLBGAAPKM
SCHEMBL706220 0.77 PIM1 (0.71) MEN1KMT2APOLBGAAPKM
SCHEMBL10091758 0.76 MEN1 (0.52) MEN1KMT2APOLBGAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 MEN1 3039/4885KMT2A 1375/4885POLB 2906/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 MEN1 3039/4885KMT2A 1375/4885POLB 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.